CD274 and melanoma: Two external cohorts—the Damrauer cohort, comprising urothelial cancer patients, and the Liu cohort, consisting of advanced melanoma patients—were used to validate the predictive value of the MHC-I-dependent neoantigen presentation pathway in response to anti-PD-1/PD-L1 therapy.